Among the many questionable tactics Mylan Pharmaceuticals has pursued to boost EpiPen sales has been a surreptitious lobbying campaign to have its device added to a coveted list of preventive services that is maintained by the federal government.
Here’s why this matters: If Mylan succeeds in getting EpiPen on that list, consumers would not have to make copayments, leaving insurers or government agencies to pick up that cost. That sounds like a good deal for patients. But by taking their wallets out of the equation, Mylan minimizes the chance of a public backlash to its pricing. It could likely keep raising the price of EpiPen — largely unnoticed.
